TORONTO, Sept. 8 /CNW/ - Microbix Biosystems Inc (TSX:MBX) announced today that the Company has ceased negotiations with the previously announced vaccine manufacturer currently evaluating Microbix' yield enhancement technology. The Company is seeking to commercialize a viable vaccine yield enhancement process that can be integrated into a vaccine supplier's commercial manufacturing process. Microbix believes its novel process significantly improves manufacturing yields in vaccine production. The Company continues to generate compelling data proving the efficacy of the technology in an ongoing program to continue toward its commercialization. Microbix specializes in developing proprietary biological technologies and then commercializing those technologies through global partners. Its products include biotherapeutic drugs, vaccines, and infectious disease diagnostics. Established in 1988, Microbix is headquartered in Toronto. Its major clients are multinational manufacturers including some Fortune 500 companies. This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. %SEDAR: 00004220E